Brainstorm cell therapeutics to present at 6th annual als research symposia

Presentation on nurown phase 3 data demonstrating evidence of biological effect in als; biomarker data reinforce clinical outcomes new york , nov. 17, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th annual als research symposium hosted by als one. the presentation will feature new analyses from the nurown placebo-controlled phase 3 amyotrophic lateral sclerosis (als) trial that highlight the biological effect of nurown through csf biomarker data.
BCLI Ratings Summary
BCLI Quant Ranking